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Abstract
Background: Reasons for race and gender differences in controlling elevated low density lipoprotein (LDL) cholesterol
may be related to variations in prescribed lipid-lowering therapy. We examined the effect of lipid-lowering drug
treatment and potency on time until LDL control for black and white women and men with a baseline elevated LDL.
Methods: We studied 3,484 older hypertensive patients with dyslipidemia in 6 primary care practices over a 4-year
timeframe. Potency of lipid-lowering drugs calculated for each treated day and summed to assess total potency for
at least 6 and up to 24 months. Cox models of time to LDL control within two years and logistic regression
models of control within 6 months by race-gender adjust for: demographics, clinical, health care delivery, primary/
specialty care, LDL measurement, and drug potency.
Results: Time to LDL control decreased as lipid-lowering drug potency increased (P < 0.001). Black women (N =
1,440) received the highest potency therapy (P < 0.001) yet were less likely to achieve LDL control than white men
(N = 717) (fully adjusted hazard ratio [HR] 0.66 [95% CI 0.56-0.78]). Black men (N = 666) and white women (N =
661) also had lower adjusted HRs of LDL control (0.82 [95% CI 0.69, 0.98] and 0.75 [95% CI 0.64-0.88], respectively)
than white men. Logistic regression models of LDL control by 6 months and other sensitivity models affirmed
these results.
Conclusions: Black women and, to a lesser extent, black men and white women were less likely to achieve LDL
control than white men after accounting for lipid-lowering drug potency as well as diverse patient and provider
factors. Future work should focus on the contributions of medication adherence and response to treatment to
these clinically important differences.
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Background
Reducing low density lipoprotein (LDL) cholesterol to
levels set by National Cholesterol Education Program
Adult Treatment Panel (ATP) III guidelines decreases
the risk of death from cardiovascular disease [1] and is
cost-effective [2]. Analyses of National Health and Nutri-
tion Examination Surveys (NHANES) from 1999 to 2006
reveal persistent gender and racial differences in meeting
these standards [3]. Several studies have implicated phy-
sician’s treatment of dyslipidemia as contributing to
these differences in LDL control. Among diabetic
patients, black patients were less likely to be prescribed
statin therapy than white patients and white men were
more likely to achieve LDL control than either women or
black men [4]. An analysis of increases in doses of lipid-
lowering drugs to achieve LDL control reported no dif-
ference by race but women had fewer dose increases than
men [5]
Most studies of racial differences in achieving LDL con-
trol have been cross-sectional and do not consider the
potency of prescribed lipid-lowering drugs [6-8]. To evalu-
ate the impact of type and total dose of lipid lowering
therapy on racial and gender disparities in LDL control,
we adapted a methodology developed previously to assess
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primary care patients at increased risk of cardiovascular
disease because of hypertension and elevated LDL choles-
terol, we hypothesized that race and gender differences in
achieving LDL control would be reduced after accounting
for lipid-lowering drug potency and baseline LDL values.
Methods
Study Sample
Study patients received longitudinal care over a four-year
period (1/1/03 through 1/1/07) in 6 primary care practices
(one family medicine and 5 general internal medicine)
affiliated with an academic medical center in Philadelphia,
PA. All practices used EPIC electronic medical record sys-
tem that offers: demographics, physiologic measures, clini-
cal diagnoses, tobacco use, laboratory data, visit
attendance data, prescribed medications, and insurance
information. Electronic prescribing is required and free
samples prohibited. We linked data on providers’ gender,
race, and training level (i.e., resident, attending, and nurse
practitioner) from certification and departmental sources.
For research on hypertension [10] and cholesterol [11]
quality of care, we developed a cohort of hypertensive
black or white patients aged ≥ 18 [N = 16,910] who have
been treated for at least 6 months in a study practice. In
this study, we included only older persons whose ATP III
LDL goal is < 130 mg/dl or < 100 for those with cardiovas-
cular disease, diabetes, or a diabetes equivalent condition
[12] (Figure 1). All study subjects were followed in study
practices at least 6 months after their first high LDL.
Outcome Variables
The primary study outcome was the time in days from the
initial elevated LDL value after 1/03 until LDL control per
ATP III guidelines (i.e., < 130 mg/dl if moderate risk or <
100 mg/dl if high risk [1]) was achieved. We also exam-
ined the proportion of patients who achieved control
within 6 months after the high baseline LDL.
Predictor Variables
Our primary predictor was a four level race-gender vari-
able (i.e., women and men grouped as white or black).
Demographics included age and median household
annual income based on residence zip code in 2000 Uni-
ted States census data (http://www.census.gov). We
extracted all prescriptions (i.e., statins, fibrates, nicotinic
acid derivatives, bile acid sequestrants, and cholesterol
absorption inhibitors) during the study timeframe. To
calculate the daily potency of lipid-lowering therapy, we
assigned a weight to each lipid-lowering drug and dose
based on published data and reports on reductions in
LDL cholesterol (Table 1) [13-15]. A weight of 1.00 was
assigned to atorvastatin 10 mg per day (the most fre-
quently prescribed dose) that reduces LDL cholesterol by
a mean of 34-38%. We then determined the relative
weights for all prescribed lipid-lowering drugs and doses
based on the mean reduction in LDL. For example,
assuming a 36% LDL reduction for atorvastatin 10 mg
(the midpoint for 34-38%), pravastatin 10 mg, which has
an expected LDL reduction of 21.5%, received a weight of
.215/.36 = 0.597. Daily potency weights for drug combi-
nations such as atorvastatin plus ezetimibe were summed
for each day.
To calculate total lipid-lowering drug potency and
allow for the dynamic nature of our follow-up, we
adapted a method developed by Bailey and colleagues [9]
to assess antihypertensive drug potency and previously
used in our research [16]. First, the duration of each pre-
scription was calculated from the number of prescribed
lipid-lowering medication pills and refills and, in case of
overlapping prescriptions, we counted the most recent.
To calculate total potency, we multiplied the potency
weight of each day’s lipid-lowering therapy by days of
prescribed drug(s). For example, a patient taking atorvas-
tatin 10 mg (daily potency weight = 1) for 60 days was
assigned a value of 60 for total potency but the same
v a l u ew o u l db ea s s i g n e dt oa1 0m gd o s eo fp r a v a s t a t i n
(daily potency weight = 0.597) prescribed for 101 days.
Persons who received no treatment at all had a total
potency of 0. We created an indicator for the presence of
lipid-lowering therapy at the start of the study timeframe.
For analyses of prescribed lipid-lowering therapy, we
examined categorical and continuous specifications of
drug potency.
We categorized baseline elevated LDL cholesterol by
quartile. We also created indicators for the number of
LDL determinations in the first 6 months after the base-
line elevated LDL. Other clinical measures include: dia-
betes (i.e. ICD-9-CM 250.xx at two visits or hemoglobin
A1c ≥ 7 mg/dl); renal insufficiency (i.e., creatinine > 2);
other vascular diseases (i.e. coronary artery disease, per-
ipheral vascular disease, cerebrovascular disease); and 28
non-cardiovascular comorbidities (e.g. arthritis, gastroe-
sophageal reflux/gastritis) as reported previously [10].
Smoking status was categorized as currently smoking,
not smoking, or not recorded. We calculated the maxi-
mum number of concurrent antihypertensive drugs pre-
scribed within the study timeframe.
Health care variables included: insurance type and
attendance to scheduled primary care visits within a 6-
year interval (i.e., 1/02 to 1/07 categorized in quartiles).
Primary care provider characteristics were: gender, race,
type, and workload (in quartiles) based on the maximum
annual patient visits in the study timeframe.
Analyses
The cohort was followed for at least 6 months to a max-
imum of 24 months to determine if LDL cholesterol
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Page 2 of 10control per ATP III guidelines was achieved. We con-
ducted two types of analyses. Our first outcome was
time until LDL cholesterol control examined using sur-
vival analysis methods with Cox proportional hazards
models, censoring if a subject did not achieve LDL con-
trol by 6 months after the last visit or the end of the
study. We examined Kaplan-Meier curves of time until
LDL control for all key variables as well as proportional
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Figure 1 Derivation of Study Cohort of Older Hypertensive Patients with Dyslipidemia.
Table 1 Relative Daily Potency of the HMG-CoA Reductase Inhibitors [Statins] and Non-statin Lipid-lowering Drugs
Drug Daily dose range
in study population
Effect on LDL Cholesterol*
[% decrease]
Relative potency† of lowest and highest dose
Statins
Atorvastatin 5-80 mg 32-50% 0.89, 1.39
Fluvastatin 20-80 mg 22-35% 0.61, 0.97
Lovastatin 10-120 mg 21-50% 0.58, 1.39
Pravastatin 5-320 mg 15-40% 0.42, 1.11
Rosuvastatin 2.2-60 mg 39-60% 1.08, 1.67
Simvastatin 5-160 mg 22-50% 0.61, 1.39
Non-Statins
Cholestyramine 4-16 g 4-9% 0.10, 0.25
Colesevelam 625-3750 mg 5-10% 0.14, 0.28
Colestipol 1-10 g 5-10% 0.14, 0.28
Ezetimibe 5-30 mg 10-20% 0.28, 0.56
Fenofibrate 27-320 mg 5-10% 0.14, 0.28
Gemfibrazole 300-1200 mg 5-10% 0.14, 0.28
Niacin 250-3000 mg 4-9% 0.10, 0.25
Omega 3-12 mg 4-5% 0.10, 0.14
* References 13-15.
† Atorvastatin 10 mg per day assigned a daily potency weight of 1.
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control by 6 months after the initial elevated LDL, we
estimated logistic regression models.
Among treated persons, lipid-lowering drug potency
was examined both as a continuous variable and in two
categories: low (a mean daily potency weight of 1 for
less than half of the mean number of treated days [n =
450]) versus high (a mean potency weight of 1 for more
than half of the mean treated days). Persons with no
treatment were considered as a third category.
In a series of Cox proportional hazards models, we
sequentially added 5 sets of variables to assess changes in
the hazard ratios for each race-gender group versus white
men. The sets of variables were: demographics; clinical;
health care; primary care provider and specialty care; base-
line LDL, frequency of LDL checks, and lipid-lowering
drug potency. We included an indicator of time [days]
since the initial LDL was obtained. We also fit parametric
Weibull survival models with physician level frailties to
examine the effect of clustering on primary care provider
but the conclusions were similar to reported models and
are not shown.
The logistic regression models adjust for all study vari-
ables. Sensitivity analyses examined stability of the gender-
race association in logistic models for subsets of subjects
with the same insurance (Medicare or commercial), neigh-
borhood income level, or age group. We also estimated
models among only subjects with diabetes or another con-
dition warranting a lower [< 100 mg/dl] LDL goal.
Role of the Funding Source
Research funding was provided by Pfizer, Inc. to the Uni-
versity of Pennsylvania. Authors from the University of
Pennsylvania and Penn State College of Medicine con-
ducted all analyses and wrote the manuscript. One author
is a Pfizer employee, but he did not have direct access to
study data. This author obtained study funding, contribu-
ted to the study design and reviewed the manuscript. Pfi-
zer had no role in the decision to submit the manuscript
for publication. This project was approved by the Univer-
sity of Pennsylvania Institutional Review Board.
Results
The derivation of the study cohort is shown in Figure 1.
Eighty-nine percent of patients aged 18 or older had base-
line LDL cholesterol determination and, of these, 39% had
an elevated level. Among the 3,484 study subjects with ele-
vated LDL cholesterol, women were older than men and
black subjects had lower income levels than white subjects.
Women were more likely to be Medicare-enrolled than
men and black patients were more likely to be Medicaid-
enrolled than white patients (Table 2).
Women had higher baseline LDL levels than men but,
within each gender group, the mean LDL values did not
differ by race (Table 2). Time until a follow-up LDL
determination did not significantly differ by race-gender
group (P = 0.10) but men had significantly more LDL
determinations within 6 months after the baseline ele-
vated LDL cholesterol than women. LDL control at 6
months after baseline differed significantly by race-
gender group but was poorest for black women.
Higher proportions of black patients were diagnosed
with vascular disease, diabetes, or renal insufficiency than
white patients. Black women had more non-cardiovascu-
lar comorbid conditions than the other race-gender
groups. Current tobacco use was more prevalent in black
men. Fifty-five percent of the cohort was prescribed
lipid-lowering therapy during the study timeframe; black
women were the most likely to be treated of the four
race-gender groups. Among those who were treated,
black women and men were prescribed more potent
lipid-lowering medications than white women or men.
Black women were also treated for more days than the
other gender-race groups and had higher lipid-lowering
drug potency.
In regard to health care, white patients had fewer
annual arrived visits but black patients were less adherent
to scheduled visits. Black patients were prescribed more
antihypertensive medications. Most of the 202 primary
care providers were white and more than half were
women. Attending physicians delivered care to the
majority of patients but treated fewer black patients.
Higher lipid-lowering drug potency was associated with
shorter time to LDL control [P < 0.001] (Figure 2). Addi-
tional analyses showed that patients who were being pre-
scribed lipid-lowering therapy at the time of the baseline
elevated LDL did not differ in time to LDL control from
those on no therapy at baseline (P = 0.83).
However, the mean unadjusted time until LDL control
differed significantly (P < 0.001) by gender-race group:
540 days for black women, 505 days for white women,
510 days for black men, and 444 days for white men
(Figure 3). Note that these times are shorter than the
t o t a lt i m eo nt h e r a p yr e p o r t e di nT a b l e2s i n c ep a t i e n t
remained on lipid lower therapy even after achieving
LDL control. At each potency level, black women had a
lower unadjusted hazard of achieving control than white
men (Figure 4). Compared with white men, the unad-
justed hazards of achieving LDL control were reduced by
39% for black women and by 25% for black men and 28%
for white women (Table 3). Adjusting for demographic,
clinical, health care and provider characteristics produced
little change in these results. Adjusting for baseline LDL
cholesterol, frequency of LDL checks (continuous), and
lipid-lowering drug potency moderated these effects
somewhat but the hazards of LDL control remained sig-
nificantly lower for all three groups versus white men
(Table 3). In the final model, high potency lipid-lowering
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Page 4 of 10Table 2 Characteristics of Four Race-Gender Groups of Primary Care Hypertensive Patients with High Baseline LDL
Cholesterol
Characteristic Black
women
(N = 1,440)
Black
men
(N = 666)
White women
(N = 661)
White
men
(N = 717)
P Value
Baseline LDL cholesterol [mg/dl], mean [SD] 142.8 (29.9) 138.9 (28.0) 144.0 (24.3) 137.2 (23.4) < 0.001
LDL control by 6 months after baseline, % 16.8 18.9 20.3 28.5 < 0.001
LDL cholesterol tests within 6 months after baseline, N [SD] 0.85 (0.75) 0.90 (0.79) 0.80 (0.77) 0.92 (0.90) 0.026
Sociodemographic
Age [years], mean [SD] 68.4 (9.7) 61.4 (11.1) 68.4 (9.9) 62.3 (10.5) < 0.001
Median income in zipcode of residence, mean $ [SD] 28,360 (10,904) 30,692 (12,825) 57,004
(23,790)
58,680 (23,464) < 0.001
Insurance type [%]
Commercial 46.4 60.7 57.5 72.5 < 0.001
Medicaid 17.4 14.9 2.0 2.2
Medicare 35.4 22.8 40.2 24.8
Self pay 0.8 1.7 0.3 0.4
LDL Cholesterol
Baseline LDL [mg/dl], mean [SD] 142.8 (29.9) 138.9 (28.0) 144.0 (24.3) 137.2 (23.4) < 0.001
LDL tests within 6 months mean [SD] 0.85 (0.75) 0.90 (0.79) 0.80 (0.77) 0.92 (0.90) 0.026
LDL control by 6 months after baseline, % 16.8 18.9 20.3 28.5 < 0.001
Clinical
Vascular disease, % 30.1 28.2 21.2 21.1 < 0.001
Diabetes, % 41.5 46.2 19.5 31.1 < 0.001
Renal insufficiency, % 13.3 21.9 3.3 9.6 < 0.001
Unrelated comorbidities, # 6.3 5.4 5.5 4.9 < 0.001
Tobacco use, %
Current 11.2 14.9 5.0 10.3 < 0.001
No 55.3 45.2 70.8 54.7
Not recorded 33.5 39.9 24.2 35.0
Lipid-lowering Drug Therapy
Treated (%) 57.4% 54.7% 52.5% 53.7% 0.134
Potency per day of treatment, mean (SD) 0.96 (0.26) 0.97 (0.25) 0.90 (0.25) 0.91 (0.3) < 0.001
Duration of treatment, days, mean (SD) 964.5 (550.3) 919.6 (537.6) 887.3 (544.9) 911.7 (548.4) 0.01
Total potency, categorical (treated only)
None, % 42.6 45.4 47.5 46.3
Lower [≤840],% 26.5 28.5 26.5 30.3 0.007
Higher [> 840],% 31.0 26.1 26.0 23.4
Health Care
Primary care arrived visits per year, mean (SD) 6.3 (4.2) 6.5 (4.6) 5.8 (3.7) 5.7 (6.1) 0.002
Kept < 60% of scheduled visits, % 19.7 20.7 13.0 10.2 < 0.001
Maximum concurrent anti-hypertensive drugs, mean N (SD) 2.5 (1.3) 2.3 (1.3) 1.9 (1.1) 1.8 (1.2) < 0.001
Provider (N)
Race, %
White (157) 60.7 62.5 90.6 91.2 < 0.001
Asian (27) 11.7 7.7 3.3 2.5
Other Minority (18) 27.6 30.0 6.1 6.3
Gender, %
Female (110) 60.3 47.3 53.7 31.3 < 0.001
Type, %
Attending (74) 56.7 61.0 69.6 73.1 < 0.001
Resident (105) 17.0 16.2 7.9 8.4
Nurse practitioner/Physician assistant (23) 26.3 22.8 22.5 18.6
Annual arrived visits to 1916.8 1980.1 2009.0 2202.7 < 0.001
provider, mean N (SD) (1464.7) (1454.6) (1207.5) (1404.4)
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with LDL control of all covariates with an adjusted
hazard of 1.85 (95% CI: 1.63, 2.1) for high potency rela-
tive no treatment (Table 4). Racial disparities in LDL
control were most evident for subjects receiving higher
potency therapy (Figure 5). In separate models among
persons who only have diabetes or another risk factor
with a lower LDL control standard (< 100 mg/dl), gen-
der-race differences was similar to those in the entire
cohort.
Analysis of the adjusted odds of LDL control by 6
months showed similar associations with a fully adjusted
odds ratios for black women of 0.53 (95% CI: 0.40 -
0.71), for white women of 0.64 (95% CI: 0.49 - 0.85), for
black men of 0.65 (95% CI: 0.48 - 0.89) versus white
men. Even though black patients were more likely to
have diabetes and other conditions that require a lower
LDL goal (< 100 mg/dl), analyses restricted to only
patients with these conditions showed similar odds
ratios for each of the gender-race groups. Additional
stratified analyses showed similar gender-race effects
among: persons with Medicare insurance or commercial
insurance, among persons with low income, and among
persons with the same age category.
Discussion
The US National Ambulatory Medical Care Survey from
2005 revealed marked inequities in assessment and man-
agement of dyslipidemia by respondents’ race-ethnicity
[17]. Among nearly 3,500 older primary care patients
with hypertension and dyslipidemia, we use a novel
approach to assessing the potency of prescribed lipid
lowering therapy as a potential explanatory factor contri-
buting to these inequities. Contrary to other studies that
reported less treatment for dyslipidemia for women
[18,19] or fewer lipid-lowering dose changes among trea-
ted women [5], the women in our study cohort were
more likely to be treated for hyperlipidemia and pre-
scribed more intensive lipid lowering therapy than men
the same racial group. Indeed, black study women were
the most likely to be treated for dyslipidemia and, when
treated, were prescribed more potent treatment than
black men, white women and white men. Mark et al.
reported that black patients were less likely to have their
lipid-lowering drugs switched, augmented, or titrated but
did not examine achievement of LDL control goals [20].
In contrast, we find that, even though black patients
received more intensive treatment, racial differences in
achieving LDL cholesterol targets persisted. After two
years, two-thirds of white men achieved LDL control ver-
sus only 50% or less of black men and women as well as
white women. These sustained differences in LDL control
are clinically significant [2] and may play a role in
observed disparities in clinical outcomes of cardiovascu-
lar disease [21].
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lipid-lowering therapy but we could not evaluate the
impact of counseling about a low cholesterol diet or
adherence to the medication. In regard to unmeasured
patient-related factors, inherent genetic differences may
attenuate response to lipid-lowering therapy. However, in
more controlled circumstances such as clinical trials,
women and black men have responded to lipid-lowering
therapy similarly to white men [22-24] and women [25].
Differences in adherence to lipid-lowering therapy may
explain some of these associations; Chan and colleagues
reported that men were more adherent to statins than
women as were persons who lived in predominantly non-
black compared with primarily black neighborhoods [26].
Among Medicaid enrollees, Litaker reported that black
patients were 25% less likely to persist in taking lipid-low-
ering drugs than white patients [27]. Statin nonadherence
may reflect deficient office based monitoring [28]; in our
analysis, we accounted for adherence to office visits and
frequency of LDL determinations.
Research has also implicated negative patient attitudes
about lipid-lowering therapy [29,30] and limited under-
standing of the need for long-term therapy [29,31].
Increased patient education by the physician or an allied
health personnel has been endorsed to address these atti-
tudinal and knowledge barriers [32]. Our analyses did not
adjust for restrictive pharmacy benefit plans or cost bar-
riers to achieving LDL control [33]. Fortunately, generic
statins have greatly reduced the cost of therapy [34] as
have value-based drug benefit programs [35]. In sensitivity
analyses, gender-race differences persisted among patients
with Medicare insurance or those with commercial insur-
ance. Chan and colleagues reported that adjusting for
patient and physician characteristics as well as out-of-
pocket costs did not significantly explain the variation in
adherence to statins [26].
Overall, our cohort was prescribed relatively low
potency lipid-lowering therapy, the equivalent of approxi-
mately simvastatin 20 mg per day. In a Norwegian study,
the mean dose of prescribed lipid-lowering drugs was
25 mg for simvastatin and 22 mg for atorvastatin but,
there too, doses were low [36]. Based on a recent simula-
tion study, more tailored statin treatment would save
lives if physicians initiated treatment with simvastatin
40 mg for persons at intermediate cardiovascular risk
dose and atorvastatin 40 mg for persons at high risk [37].
The reasons for the conservative dosing of lipid-lowering
drugs for our cohort are unknown but may reflect con-
cerns about side effects at higher doses.
Our study has other limitations. First, the gender-race
groups differed in multiple characteristics but, the differ-
ences in goal attainment persisted even when restricting
the study analyses to persons with diabetes or other risk
factor that requires a lower LDL standard. Second, our
measure of total potency is the same for persons who
take high doses for a short time or low doses for a longer
time. However, racial differences persisted among only
patients prescribed higher potency treatment. Third, the
total pill burden may have negatively affected acceptance
or persistence in taking lipid-lowering therapy. We did
consider the number of prescribed antihypertensive
drugs as well as the number of comorbidities that require
more medications. In other analyses, patients with a
greater number of concurrent medications were more
likely to be adherent to statin therapy [38]. Fourth, we
also could not consider the effect of therapeutic substitu-
tions that can affect adherence [39]. Fifth, specialists
might have prescribed these drugs but they share the
Table 3 Association of Race-Gender Groups with Time until LDL Cholesterol Control in Cox Proportional Hazards
Models Adjusted for Sequentially Added Sets of Variables
Variables Added to Model
Unadjusted Socio-
demographic
Clinical
Comorbidities
Health Care Primary Care Provider LDL Management
Hazard Ratio [95% CI]
Race-gender Group
Black Women 0.61
[0.53-0.69]‡
0.65
[0.56-0.76]‡
0.63
[0.54-0.74]‡
0.64
[0.54-0.75]‡
0.63
[0.53-0.74]‡
0.66
[0.56-0.78]‡
Black Men 0.75
[0.64-0.86]‡
0.78
[0.66-0.93]†
0.77
[0.65-0.91]†
0.79
[0.66-0.94]†
0.73
[0.63-0.86]†
0.82
[0.69-0.98]*
White Women 0.72
[0.62-0.83]‡
0.75
[0.64-0.87]‡
0.74
[0.64-0.86]‡
0.75
[0.64-0.87]‡
0.78
[0.65-0.93]‡
0.75
[0.64-0.88]†
White Men 1.0 1.0 1.0 1.0 1.0 1.0
*P < 0.05
† P ≤ 0.01
‡ P ≤ 0.001
Demographics [i.e., age, neighborhood income]; clinical comorbidities [i.e., vascular disease, diabetes, renal insufficiency, unrelated comorbidities, smoking]; health
care [i.e., insurance, number of annual visits; visit adherence; antihypertensive medications]; primary care provider [i.e. type, race, gender, workload]; LDL
management [i.e., baseline LDL, LDL checks within 6 months, and lipid-lowering drug potency].
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Hazard 95% CI
Characteristic Ratio Lower Upper P value
Gender-race
Black women 0.66 0.56 0.78 < 0.0001
Black men 0.82 0.69 0.98 0.029
White women 0.75 0.64 0.88 < 0.0001
Baseline LDL cholesterol (quartile)
Second 0.89 0.78 1.01 0.082
Third 0.67 0.58 0.77 < 0.0001
Fourth 0.48 0.42 0.56 < 0.0001
Total lipid-lowering drug potency
Low 1.23 1.08 1.41 0.001
High 1.85 1.63 2.1 < 0.0001
LDL checks in first 6 months
1-2 2.79 2.33 3.35 < 0.0001
3+ 4.41 3.58 5.44 < 0.0001
Age [years]
61-70 1.1 0.98 1.25 0.114
71-80 1.28 1.11 1.47 0.001
> 80 1 0.84 1.21 0.96
Median neighborhood (per $1000 increase) 1 1 1.01 0.016
Smoking status
Current 0.99 0.84 1.18 0.934
Not reported 1.04 0.93 1.17 0.512
Vascular disease 0.8 0.7 0.92 0.001
Unrelated comorbidities (per comorbidity) 1.04 1.02 1.06 < 0.0001
Diabetes 0.81 0.72 0.9 < 0.0001
Chronic renal insufficiency 1.26 1.05 1.52 0.012
Insurance type
Medicaid 0.87 0.72 1.04 0.128
Medicare 0.97 0.86 1.1 0.623
Self pay 0.85 0.42 1.71 0.641
High patient adherence to visits 1.31 1.13 1.51 < 0.0001
Antihypertensive drugs (N) 0.98 0.93 1.02 0.299
Provider type
Resident 1.15 0.96 1.38 0.117
Other clinician 1.01 0.86 1.19 0.897
Provider race
Asian 1.07 0.85 1.33 0.57
Black or other 0.99 0.84 1.16 0.877
Female provider 1.03 0.9 1.18 0.645
Provider workload (quartile of annual visits)
Second 1.02 0.88 1.19 0.788
Third 0.96 0.82 1.12 0.58
Fourth 0.94 0.78 1.14 0.535
Patient visits (quartile of annual visits)
Second 1.01 0.88 1.16 0.896
Third 1.09 0.95 1.25 0.24
Fourth 1.01 0.87 1.18 0.867
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Page 8 of 10same electronic medical record and medication reconci-
liation is required at each primary care visit.
Our study does not support the theory that differences
in receiving lipid-lowering therapy or, when treated,
potency of the prescribed therapy can account for
widely observed racial- and gender-based differences in
LDL cholesterol control. These data should direct atten-
tion to evaluating and addressing barriers to lipid-lower-
ing drug adherence especially among black patients
regardless of gender and white women. Promising
approaches have been reported. For example, a health
professional counseling by telephone significantly
increased persistence with lipid-lowering medication but
still only half of the subjects achieved LDL control
within a year [40]. Finally, our study also reveals that
primary care physicians may be prescribing sub-optimal
doses of statin therapy demonstrating important oppor-
tunities to improve quality of care.
Conclusions
In this study of 3,484 older hypertensive patients with dys-
lipidemia in 6 primary care practices, we found that black
women, in spite of receiving the highest potency therapy,
were less likely to achieve LDL control than white men.
To a lesser extent, black men and white women were also
less likely to achieve LDL control than white men after
accounting for lipid-lowering drug potency as well as
diverse patient and provider factors. Future work should
focus on the contributions of medication adherence and
response to treatment to these clinically important
differences.
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